Baxalta Inc

Latest Baxalta Inc News and Updates

  • uploads///hemophilia market size
    Company & Industry Overviews

    Could Baxalta Maintain Its Leadership in the Hemophilia Space?

    Baxalta’s (BXLT) hemophilia portfolio comprises of Advate, Adynovate, Rixubis, Recombinate, Hemofil M, Immunate, Immunine, and Prothromplex Total.

    By Jillian Dabney
  • uploads///hemophilia drugs
    Company & Industry Overviews

    What Are the Current Treatment Options for Hemophilia?

    Hemophilia treatment primarily includes factor replacement therapy and prolonged half-life therapy such as factor VIII or factor IX infusion.

    By Jillian Dabney
  • uploads///Graph pipeline
    Company & Industry Overviews

    BMN 270: A Big Valuation Catalyst for BioMarin

    On March 1, 2016, BioMarin received orphan drug designation for BMN 270 from the FDA. BioMarin’s stock jumped by about 6.96% the same day.

    By Jillian Dabney
  • uploads///Part  Graph
    Company & Industry Overviews

    BioMarin Withdraws Application for Kyndrisa: Stock Falls 2.5%

    As of June 1, 2016, BioMarin Pharmaceutical (BMRN) was the most underperforming stock among the large-cap stocks of the SPDR S&P Biotech ETF (XBI).

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    Shire’s Shareholders Approve Baxalta Merger: What’s Next?

    Shire (SHPG) performed the worst among the large-cap stocks of the iShares Nasdaq Biotechnology ETF (IBB) on May 27, 2016.

    By Peter Neil
  • uploads///hemophilia
    Company & Industry Overviews

    Could Gene Therapy Be a Next-Generation Treatment for Hemophilia?

    Gene therapy is the emerging platform for hemophilia care. If approved, it would be a paradigm.

    By Jillian Dabney
  • uploads///product portfolio
    Company & Industry Overviews

    A Look at Baxalta’s Product Segments

    Baxalta’s (BXLT) product portfolio can be divided into three parts: hematology, immunology, and oncology.

    By Jillian Dabney
  • uploads///Share price after shire baxalta deal
    Company & Industry Overviews

    The Shire-Baxalta Merger: A Look at the Details

    Following news of the Shire-Baxalta merger, Baxalta’s share price rose and Shire’s share price fell.

    By Jillian Dabney
  • uploads///strategic initiatives
    Company & Industry Overviews

    How Baxter’s Biosciences Spin-off into Baxalta Improved Its Valuation

    On July 1, 2015, Baxter separated its Biosciences division into a new entity named Baxalta in an effort to divest risky segments and streamline operations.

    By Sarah Collins
  • uploads///BXLT SHPG combination
    Miscellaneous

    The Baxalta–Shire merger: Basics of Shire Pharmaceuticals

    Shire is a biopharmaceutical company that focuses on rare diseases. Shire is best known for its treatments in ADHD, and the market here is quite large.

    By Brent Nyitray, CFA, MBA
  • uploads///BXLT SHPG synergies
    Miscellaneous

    Growth and Synergies Drive the Baxalta–Shire Merger

    The Baxalta–Shire merger could create the top platform for rare diseases in the world. Baxalta brings Advate, a treatment for hemophilia, a rare blood disease.

    By Brent Nyitray, CFA, MBA
  • uploads///Vanguard  Index Fund Investor Class VFINX
    Company & Industry Overviews

    US Stock Indexes Fell in December amid Falling Oil Prices

    Let’s see why US stock indexes fell. The three US equity indexes that we review in this December recap series fell from November 30 to December 31, 2015.

    By Lynn Noah
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.